Please login to the form below

Maximising ROI from mature brands

News that Eli Lilly and Co has forecast a drop in 2014 profits and reduced its sales outlook because of generic competition to its Cymbalta antidepressant and Evista drug for osteoporosis, underlines the challenges that pharma companies face when patents expire.   

Read the full article here:

9th May 2014